Hepatitis D Epidemiology Forecast 2025-2034

Hepatitis D is estimated to affect approximately 5% of the global population having a chronic infection with the hepatitis B virus, as per the World Health Organisation (WHO). The combination of hepatitis D and hepatitis B infection can cause rapid progression towards hepatocellular carcinoma and liver-related death.

Hepatitis D Epidemiology Forecast Report Coverage

The “Hepatitis D Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hepatitis D. It projects the future incidence and prevalence rates of hepatitis D across various populations. The study covers age and type as major determinants of the hepatitis D-affected population. The report highlights patterns in the prevalence of hepatitis D over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of hepatitis D in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Hepatitis D: Disease Overview

Hepatitis D (HDV) refers to a viral infection that only occurs in people already infected with hepatitis B (HBV). This viral infection can accelerate the progression of liver disease, leading to cirrhosis and liver cancer. Transmission of hepatitis D can happen through contact with infected blood, commonly through sharing needles, unregulated blood transfusions, or other unsafe medical practices. Jaundice, fatigue, abdominal pain, and dark urine are some of the common symptoms of a hepatitis D viral infection.

Hepatitis D: Treatment Overview

Pegylated interferon-alpha, an antiviral medication, is the widely used treatment for chronic hepatitis D. It helps to reduce viral replication and may improve liver function. In severe cases, where there is significant liver damage (like cirrhosis or liver failure), a liver transplant may be needed. Since hepatitis D can only infect people who are already infected with hepatitis B, vaccinating against hepatitis B is the best prevention for HDV. Increasing research and clinical trials on potential therapies for hepatitis D is likely to advance treatment options.

Epidemiology

The hepatitis D epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for hepatitis D by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hepatitis D and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• The World Health Organization (WHO) states that 5% of people suffering from a chronic hepatitis B virus (HBV) infection are affected by the hepatitis D virus.
• It is reported that over 90% of active hepatitis B infection patients who acquire hepatitis D later develop a chronic HDV infection that persists for more than 6 months.
• In the United States, roughly 100,000 people are estimated to have an HBV/HDV combined infection.
• In a 2020 study published in the Journal of Hepatology in collaboration with the WHO, it was found that HDV co-infection could account for about 1 in 5 cases of liver disease and liver cancer in individuals with hepatitis B (HBV) infection.

Country-wise Hepatitis D Epidemiology

The Hepatitis D epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of hepatitis D varies significantly between countries due to differences in hepatitis B prevalence, healthcare access, and risk factors like injection drug use. Public health measures, such as hepatitis B vaccination, is reported to significantly impact the spread of hepatitis D. In countries like Germany, Italy, Spain, and France, the prevalence of hepatitis D has remained around 8-10% over the last 10 to 15 years, where majority of immigrants come from places like Turkey, Eastern Europe, and the former Soviet Union.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hepatitis D based on several factors.
• The Hepatitis D Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of hepatitis D are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of hepatitis D epidemiology in the 8 major markets?
• What will be the total number of patients with hepatitis D across the 8 major markets during the forecast period?
• What was the country-wise prevalence of hepatitis D in the 8 major markets in the historical period?
• Which country will have the highest number of hepatitis D patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of hepatitis D during the forecast period of 2025-2034?
• What are the currently available treatments for hepatitis D?
• What are the disease risks, signs, symptoms, and unmet needs of hepatitis D?

This product will be delivered within 3-5 business days.